Group 1 - Compass Pathways plc is a biotechnology company focused on improving patient access to evidence-based innovations in mental health [1] - The company will participate in the Stifel 2026 Virtual CNS Forum on March 18, 2026, including a fireside chat at 10:30 AM ET [1] - Compass Pathways is developing COMP360, a synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA for treatment-resistant depression [1] Group 2 - The company announced the exercise of 35,059,448 warrants, generating approximately $200 million in proceeds [1] - Compass Pathways is also attending the TD Cowen 46th Annual Healthcare Conference from March 2-4, 2026, with a fireside chat scheduled for March 3, 2026 [1] - The company priced a public offering of 17,500,000 American Depositary Shares (ADSs) at $8.00 per ADS, raising $150 million [1]